# Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy

> **NCT02296021** · PHASE4 · COMPLETED · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 612 (actual)

## Conditions studied

- Gastritis
- Peptic Ulcer
- Dyspepsia

## Interventions

- **DRUG:** Berberine
- **DRUG:** Bismuth
- **DRUG:** esomeprazole
- **DRUG:** amoxicillin
- **DRUG:** clarithromycin

## Key facts

- **NCT ID:** NCT02296021
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2015-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296021, "Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT02296021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*